Drug Profile

MEM ANT3310

Alternative Names: MEM-ANT3310; SBLi-Antabio

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Antabio
Class Anti-infectives; Antibacterials; Small molecules; Urinary anti-infective agents
Mechanism of Action Beta lactamase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Intra-abdominal infections; Kidney disorders; Nosocomial infections; Urinary tract infections

Most Recent Events

28 Aug 2025 Chemical structure information added.
10 Jul 2025 Antabio completes a phase-I clinical trials in Kidney disorders (Combination therapy) in Germany (IV) (NCT06527677)
28 Apr 2025 Antabio initiates a phase I pharmacokinetic trial in healthy volunteers in USA (IV, Infusion) (NCT06916156)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com